Molecular Determinants of Outcomes in Relapsed or Refractory MCL Treated With Ibrutinib or Temsirolimus
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
Leukemia 2022 Aug 13;[EPub Ahead of Print], CL Freeman, P Pararajalingam, L Jin, S Balasubramanian, A Jiang, W Xu, M Grau, M Zapukhlyak, M Boyle, B Hodkinson, M Schaffer, C Enny, S Deshpande, S Sun, J Vermeulen, RD Morin, DW Scott, G LenzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.